Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combining tissue biomarkers with mpMRI to diagnose clinically significant prostate cancer. Analysis of 21 biomarkers in the PICTURE study.
Stopka-Farooqui U, Stavrinides V, Simpson BS, Qureshi H, Carmona Echevierra LM, Pye H, Ahmed Z, Alawami MF, Kay JD, Olivier J, Heavey S, Patel D, Freeman A, Haider A, Moore CM, Ahmed HU, Whitaker HC. Stopka-Farooqui U, et al. Among authors: stavrinides v. Prostate Cancer Prostatic Dis. 2024 Nov 22. doi: 10.1038/s41391-024-00920-1. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39578642
Multiplex imaging of localized prostate tumors reveals altered spatial organization of AR-positive cells in the microenvironment.
Ak Ç, Sayar Z, Thibault G, Burlingame EA, Kuykendall MJ, Eng J, Chitsazan A, Chin K, Adey AC, Boniface C, Spellman PT, Thomas GV, Kopp RP, Demir E, Chang YH, Stavrinides V, Eksi SE. Ak Ç, et al. Among authors: stavrinides v. iScience. 2024 Aug 3;27(9):110668. doi: 10.1016/j.isci.2024.110668. eCollection 2024 Sep 20. iScience. 2024. PMID: 39246442 Free PMC article.
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer.
Fernandez-Mateos J, Cresswell GD, Trahearn N, Webb K, Sakr C, Lampis A, Stuttle C, Corbishley CM, Stavrinides V, Zapata L, Spiteri I, Heide T, Gallagher L, James C, Ramazzotti D, Gao A, Kote-Jarai Z, Acar A, Truelove L, Proszek P, Murray J, Reid A, Wilkins A, Hubank M, Eeles R, Dearnaley D, Sottoriva A. Fernandez-Mateos J, et al. Among authors: stavrinides v. Nat Cancer. 2024 Sep;5(9):1334-1351. doi: 10.1038/s43018-024-00787-0. Epub 2024 Jul 12. Nat Cancer. 2024. PMID: 38997466 Free PMC article.
Magnetic Resonance Imaging Follow-up of Targeted Biopsy-negative Prostate Lesions.
Stavrinides V, Eksi E, Finn R, Texeira-Mendes L, Rana S, Trahearn N, Grey A, Giganti F, Huet E, Fiard G, Freeman A, Haider A, Allen C, Kirkham A, Cole AP, Collins T, Pendse D, Dickinson L, Punwani S, Pashayan N, Emberton M, Moore CM, Orczyk C. Stavrinides V, et al. Eur Urol Focus. 2023 Sep;9(5):781-787. doi: 10.1016/j.euf.2023.03.011. Epub 2023 Apr 6. Eur Urol Focus. 2023. PMID: 37031096 Free article.
Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial.
Stavrinides V, Norris JM, Karapanagiotis S, Giganti F, Grey A, Trahearn N, Freeman A, Haider A, Carmona Echeverría LM, Bott SRJ, Brown LC, Burns-Cox N, Dudderidge TJ, El-Shater Bosaily A, Ghei M, Henderson A, Hindley RG, Kaplan RS, Oldroyd R, Parker C, Persad R, Rosario DJ, Shergill IS, Winkler M, Kirkham A, Punwani S, Whitaker HC, Ahmed HU, Emberton M; PROMIS Group. Stavrinides V, et al. Radiology. 2023 Apr;307(1):e220762. doi: 10.1148/radiol.220762. Epub 2022 Dec 13. Radiology. 2023. PMID: 36511804 Free PMC article.
Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort.
Marenghi C, Qiu Z, Helleman J, Nieboer D, Rubio-Briones J, Carroll PR, Lee LS, Valdagni R, Boutros PC, Nicolai N; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Marenghi C, et al. Cancers (Basel). 2022 Jul 22;14(15):3558. doi: 10.3390/cancers14153558. Cancers (Basel). 2022. PMID: 35892817 Free PMC article.
Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative.
Remmers S, Helleman J, Nieboer D, Trock B, Hyndman ME, Moore CM, Gnanapragasam V, Shiong Lee L, Elhage O, Klotz L, Carroll P, Pickles T, Bjartell A, Robert G, Frydenberg M, Sugimoto M, Ehdaie B, Morgan TM, Rubio-Briones J, Semjonow A, Bangma CH, Roobol MJ; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Remmers S, et al. Eur Urol Open Sci. 2022 Jun 14;41:126-133. doi: 10.1016/j.euros.2022.05.012. eCollection 2022 Jul. Eur Urol Open Sci. 2022. PMID: 35813247 Free PMC article.
Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.
Beckmann KR, Bangma CH, Helleman J, Bjartell A, Carroll PR, Morgan T, Nieboer D, Santaolalla A, Trock BJ, Valdagni R, Roobol MJ; Global Action Plan Active Surveillance Prostate Cancer [G.A.P.3] Consortium. Beckmann KR, et al. Prostate. 2022 May;82(7):876-879. doi: 10.1002/pros.24330. Epub 2022 Mar 7. Prostate. 2022. PMID: 35254666 Free PMC article.
47 results